Meningococcal

MENINGITIS DISEASE : EVALUATION OF APPROACHES TO DEVELOP NOVEL LOW COST MULTIVALENT MENINGOCOCCAL CONJUGATE VACCINE

Key Factors
  • Meningococcal meningitis is a bacterial form of meningitis, a serious infection of the thin lining that surrounds the brain and spinal cord.
  • Meningococcal meningitis is associated with high fatality (up to 50% when untreated) and high frequency (more than 10%) of severe sequelae. Early antibiotic treatment is the most important measure to save lives and reduce complications.
  • Meningococcal meningitis is observed worldwide with about 0.3 million deaths reported in the year 2016. The highest burden of the disease is in the meningitis belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east.
  • Around 30000 cases are still reported each year from that area.
  • During 2016–2017, several meningitis outbreak were reported, the most significant being Neisseria meningitidis type C in sub-Saharan Africa, followed by type B & type W in rest of the world.
  • Twelve types of Neisseria meningitidis, called serogroups, have been identified, six of which (A, B, C, W, X and Y) can cause epidemics.

Ref: https://www.who.int/news-room/factsheets/detail/meningococcal-meningitis

The solution is

Hilleman Laboratories is exploring the development of a cost effective alternative to pentavalent conjugate vaccine using novel synthetic oligomers and improved conventional conjugates against meningococcus serogroup A, C, W135, X and Y.

THE SOLUTION IS: MULTIVALENT MENINGOCOCCAL CONJUGATE VACCINE
  • Hilleman Laboratories dual-approach on Synthetic and Conventional platforms, facilitates the following product and process advantages
    • Less complex manufacturing process.
    • Reduced, or negligible batch-to-batch variation.
    • Greater control over product quality.
    • Greater consistency of composition and enhanced purity.
  • Both the platforms have the potential to be expanded to commercial scale.
  • Both the platforms have shown very positive results in initial animal immunogenicity studies (ongoing).

MENINGOCOCCAL VACCINE: HILLEMAN LABORATORIES IS PURSUING A 2-PRONGED APPROACH TO DEVELOP CONJUGATE VACCINES USING CONVENTIONAL AND SYNTHETIC TECHNOLOGY